Role of STAT3 pathway in genitourinary tumors.
Role of STAT3 pathway in genitourinary tumors.
复制标题
DOI：
10.4155/fso.15.13
复制
发表时间：
2015-11
影响因子：
2.5
通讯作者：
Montironi R
中科院分区：
文献类型：
--
作者：
Santoni M;Conti A;Piva F;Massari F;Ciccarese C;Burattini L;Cheng L;Lopez-Beltran A;Scarpelli M;Santini D;Tortora G;Cascinu S;Montironi R
STAT3 在泌尿生殖系统肿瘤中经常失调。在前列腺癌中，STAT3 激活与格里森评分和病理分期相关，并调节癌症干细胞和上皮间质转化。此外，STAT3通过增加HIF1α和VEGF的表达促进从原位癌发展为浸润性膀胱癌并调节肾细胞癌血管生成。 STAT3 还参与转移性肾细胞癌患者对酪氨酸激酶抑制剂舒尼替尼和阿西替尼的反应，以及晚期前列腺癌患者对第二代雄激素受体抑制剂恩杂鲁胺的反应。在这篇综述中，我们描述了 STAT3 在泌尿生殖系统肿瘤中的作用，从而描述了它在未来治疗策略中的潜力。 STAT3 蛋白的调节在泌尿生殖系统肿瘤（包括前列腺癌、膀胱癌和肾癌）中经常出现功能障碍。 STAT3 参与这些肿瘤的生成，并影响它们对治疗的反应。在这篇综述中，我们描述了它在泌尿生殖肿瘤中的作用，并讨论了它在未来治疗中的应用潜力。
The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial–mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF. STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role of STAT3 in genitourinary tumors, thus describing its potential for future therapeutic strategies. Regulation of the protein STAT3 is often dysfunctional in genitourinary tumors, including prostate, bladder and kidney cancer. STAT3 is involved in the generation of these tumors and has an effect in their response to treatments. In this review, we describe its role in genitourinary tumors and discuss its potential for use in future therapies.